<p>Anna Rose Welch talks about a new whitepaper that explains why now is the best time for a U.S. biosimilars shared savings model.</p>

Anna Rose Welch talks about a new whitepaper that explains why now is the best time for a U.S. biosimilars shared savings model.

016: Can A Biosimilars Shared Savings Model Work In The U.S.?

Life Science Connect Editorial Director, Dan Schell, works with a talented and passionate group of editors. Each week, he sits down with them to discuss their pressing coverage areas, latest travels, and interesting interviews from within the life sciences landscape. His rotating cast of contributors includes Life Science Connect editors Rob Wright, Ed Miseta, Louis Garguilo, Anna Rose Welch, Erin Harris, and Matt Pillar.

Share 016: Can A Biosimilars Shared Savings Model Work In The U.S.?

Sign up to save your podcasts

016: Can A Biosimilars Shared Savings Model Work In The U.S.?

016: Can A Biosimilars Shared Savings Model Work In The U.S.?